News about the first patient dosing of CDH17 must be imminent…Rebecca mentioned at a recent conference that the CART lab manufacturing process for the 27 yo with stage 4 gastric cancer was well advanced.
This therapy could be practise changing for one of the largest cancer markets with unmet needs….good luck to all involved including patients enrolled in the trial, UPenn clinicians who developed the technology and Chimeric management/shareholders.
News about the first patient dosing of CDH17 must be...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $46.58K | 11.64M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2545728 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 16.10pm 19/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |